Technology Type

Therapeutic Modality

Regenerative Topical Therapy for Cold-Induced Skin Injury: A Field-Ready Solution to Prevent Necrosis and Amputation

07296

Hydrogel HA-Metformin topical therapy regenerates frostbitten skin, restores architecture, reduces necrosis risk, deployable field-ready.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Dermatology
Tags: Biomaterial
Polymer
Regenerative medicine
Lead Inventor: James Wang
Department: Med-Orthopedic Surgery
All Tech Innovators: James Huicong Wang
Jianying Zhang
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2025-08-19
Collections: Regenerative Medicine

Microneedle Array Delivery of Adenovirus Vectored Vaccines

05297

Microneedle arrays deliver adenovirus-vectored vaccines into skin, boosting immunogenicity and enabling universal, adjuvant-enhanced vaccination.

Technology Type: Therapeutic Modality
Technology Subtype: Vaccine - Viral Vector
Therapeutic Areas: Dermatology
Infectious Disease
Lead Inventor: Louis Falo
Department: Med-Dermatology
All Tech Innovators: Geza Erdos
Louis D. Falo Jr
Andrea A. Gambotto M.D.
Date Submitted: 2020-04-08

Novel Influenza D Virus Vaccine Strategy

06964

Single-cycle M-null IDV vaccine prompts immune protection without disease, aiming cross-species influenza D immunity.

Technology Type: Therapeutic Modality
Technology Subtype: Vaccine - subunit, recombinant, polysaccharide, or conjugate
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Influenza
Tags: Life Science
Lead Inventor: Suresh V Kuchipudi
Department: GSPH-Infectious Diseases & Microbiology
All Tech Innovators: Suresh V Kuchipudi
Santhamani Ramasamy
Date Submitted: 2024-11-08

Bacteriophage Cocktail to Treat Achromobacter

06380

Five phages form a cocktail to broaden Achromobacter targeting, offering personalized, antibiotic-sparing therapy potential.

Technology Type: Therapeutic Modality
Technology Subtype: Bacteriophage
Therapeutic Areas: Respiratory
Infectious Disease
Therapeutic Indications: Other
Lead Inventor: Daria Van Tyne
Department: Med-Medicine
All Tech Innovators: Ghady Haidar
Daria N. Van Tyne
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2023-04-20

PROTAC treatment for HIV

06285

PROTACs selectively degrade HIV Nef, restoring immune recognition and suppressing HIV replication, aiming for reservoir clearance.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Lead Inventor: Thomas Smithgall
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Lori Ann Emert-Sedlak
Allen B. Reitz
Thomas E. Smithgall
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-02-06

Innovative Small Molecule for Zika Virus Neutralization

06214

CZV1-1: first nonpeptide Zika neutralization surrogate enabling highly specific, room-temperature diagnostics and research tools.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Zika
Lead Inventor: Donald Burke
Department: GSPH-Epidemiology
All Tech Innovators: Donald S. Burke
Priscila Mayrelle Da Silva Castanha
Ernesto Torres De Azeved Marques Jr
Date Submitted: 2022-11-14
Collections: Women's & Reproductive Health

Biased GPCR Ligands as a Therapeutic Intervention Strategy for Alzheimer's Disease

06184

Biased GPCR ligands selectively block β-arrestin signaling, reduce amyloid pathology, and preserve safety in Alzheimer's models.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Neuroscience
Therapeutic Indications: Alzheimer's Disease
Lead Inventor: Amantha Thathiah
Department: Med-Neurobiology
All Tech Innovators: Yunhong Huang
Amantha Thathiah
Date Submitted: 2022-10-05

Heparanase Inhibition for Organ Preservation

05953

HPSE inhibitors added to ex vivo lung perfusion preserve endothelial glycocalyx, boost graft quality and transplant outcomes. (15 words)

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Lead Inventor: Pablo Sanchez
Department: Med-Cardiothoracic Surgery
All Tech Innovators: Kentaro Noda
Pablo Gerardo Sanchez
Date Submitted: 2022-02-03

Fully Human Fabs Binding to the CD94/NKG2A Heterodimer

05650

Fully human antibodies block CD94/NKG2A, restoring NK/T cell activity against cancer and HIV, with strong specificity.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Infectious Disease
Oncology
Therapeutic Indications: HIV
Lung Cancer - Non-Small Cell
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Yae Jin Kim
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-03-23
Collections: Women's & Reproductive Health

Small Molecule Allosteric Modulators of Class B GPCRs in the PTHR and Method to Identify Them

05559

Structure-guided discovery yields four small-molecule negative allosteric modulators of PTHR, offering oral, targeted osteoporosis therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Musculoskeletal
Endocrinology and Metabolic Diseases
Lead Inventor: Ieva Sutkeviciute
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Ivet Bahar
Pemra Doruker
Jiyoung Lee
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-11-19
Collections: Cardiometabolic
Women's & Reproductive Health

Intestinal Microbiome Modulation to Enhance Anti-Tumor Immunity

05545

Gut microbiome–driven FMT plus anti-PD-1 boosts anti-tumor immunity in PD-1–refractory melanoma patients; tolerable, durable responses.

Technology Type: Therapeutic Modality
Technology Subtype: Other Therapeutic Modality
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Lead Inventor: Diwakar Davar
Department: Med-Medicine
All Tech Innovators: Diwakar Davar
Amiran Dzutsev
Giorgio Trinchieri
Date Submitted: 2020-11-01

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2

05391

Multivalent nanobody cocktails deliver ultra-highly potent, breath-stable SARS-CoV-2 neutralization, enabling rapid, inhalable therapeutic options.

Technology Type: Therapeutic Modality
Technology Subtype: Vaccine - subunit, recombinant, polysaccharide, or conjugate
Therapeutic Areas: Infectious Disease
Lead Inventor: Yi Shi
Department: Med-Cell Biology
All Tech Innovators: Yi Shi
Yufei Xiang
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-05-30

Trabecular Meshwork Stem Cell Secretome for Treatment of Glaucoma

05099

Stem cell secretome from trabecular meshwork lowers intraocular pressure, preserves vision via non-invasive, scalable glaucoma treatment.

Technology Type: Therapeutic Modality
Technology Subtype: Protein
Therapeutic Areas: Ophthalmology
Therapeutic Indications: Glaucoma
Lead Inventor: Yiqin Du
Department: Department of Ophthalmology
All Tech Innovators: Yiqin Du
Ajay Kumar
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-08-27
Collections: Regenerative Medicine

Lung-Targeting Peptide to Deliver Diagnostic and Therapeutic Targets to the Lung

05084

Lung-targeting cell-penetrating peptides enable higher-transduction delivery of diagnostics and therapies directly to lung tissue.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Respiratory
Therapeutic Indications: Chronic Obstructive Pulmonary Disease (COPD)
Asthma
Acute respiratory failure
Tags: Platform Technology
Lead Inventor: Maliha Zahid
All Tech Innovators: Maliha Zahid
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-08-07

Novel Compounds to Inhibit TNF-Induced NF-κB Pathways

04864

Network-centric discovery yields two first-in-class small molecules selectively blocking TNF-induced NF-κB signaling, reducing off-target effects.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Tags: Autoimmune
Lead Inventor: Carlos Camacho
Department: Med-Computational and Systems Biology
All Tech Innovators: Carlos Jaime Camacho
Robin E C Lee
Date Submitted: 2019-01-22

Small Molecule Drug for Targeting Resistant Prostate Cancer

07323

New CPPI-derived small molecules act as nuclear androgen receptor degraders, suppressing resistant prostate cancer in AR-positive tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Timothy James Casad
Joel B. Nelson
Zhou Wang
Date Submitted: 2025-09-02

A Novel Mechanism for Disrupting Biofilms and Combating Antimicrobial Resistance

07134

Novel PLG0206 disrupts Staphylococcus biofilms by targeting wall teichoic acid, with low, multi-mutation resistance risk.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Infectious Disease
Tags: Coating
Drug Discovery - Target
Lead Inventor: Kenneth Urish
Department: Med-Orthopedic Surgery
All Tech Innovators: Umit Akbey
Vaughn Scott Cooper
Kenneth L. Urish Jr
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-04-02

Dipeptidyl Peptidase-4 (DPP4) Inhibitors for Inhibiting Posterior Capsular Opacification

07055

DPP4 inhibitors delivered locally prevent posterior capsular opacification by blocking TGF-β–driven EMT in lens cells.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Ophthalmology
Therapeutic Indications: Cataracts
Tags: Aging
Drug Repurposing
Lead Inventor: Kun Che Chang
Department: Med-Ophthalmology
All Tech Innovators: Kun Che Chang
Chi-Yu Chen
Pei-Kang Liu
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-01-31
Collections: Regenerative Medicine

Novel Therapy for Chondrocyte Aging and Osteoarthritis

07004

GATA4-targeting small molecule HCA42027 may restore aged chondrocyte repair, offering a potential disease-modifying OA therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Musculoskeletal
Therapeutic Indications: Heart failure
Atherosclerotic disease
Osteoarthritis
Tags: Drug Discovery - Target
Life Science
Lead Inventor: Hang Lin
Department: Med-Orthopedic Surgery
All Tech Innovators: Olivia Bartholomew
Kate Li
Hang Lin
Date Submitted: 2024-12-11
Collections: Cardiometabolic

Bait Oligonucleotides to Prevent TDP-43 Associated Neurodegeneration

06987

Dual-acting RNA chaperones (24–48 nt) prevent and dissolve TDP-43/FUS aggregates, restoring function and reducing neurodegeneration.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - RNA
Therapeutic Areas: Neuroscience
Therapeutic Indications: Parkinson's Disease
Amyotrophic lateral sclerosis (ALS)
Alzheimer's Disease
Lead Inventor: Christopher Donnelly
Department: Med-Neurobiology
All Tech Innovators: Christopher James Donnelly
James Shorter
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2024-11-30
Collections: Cell & Gene Therapy

Vasculogenic Reprogramming for Diabetic Wound Healing and Ischemic Tissue Regeneration

06874

Vasculogenic reprogramming via Tissue Nanotransfection induces vasculogenic fibroblasts, boosting diabetic wound healing and ischemic tissue regeneration.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - DNA
Therapeutic Areas: Endocrinology and Metabolic Diseases
Therapeutic Indications: Diabetes
Lead Inventor: Chandan Sen
Department: Med-Surgery
All Tech Innovators: Sujit Kumar Mohanty
Sashwati Roy
Chandan Sen
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2024-09-16
Collections: Cell & Gene Therapy
Regenerative Medicine
Cardiometabolic

New Permanent Treatment for Cerebral Aneurysms

06726

Injectable, ECM-derived embolic seals aneurysms permanently, integrating with tissue to avoid coils, recanalization, and retreatment.

Technology Type: Therapeutic Modality
Therapeutic Areas: Hematology
Lead Inventor: Seungil Kim
Department: Bioengineering
All Tech Innovators: Seungil Kim
William R. Wagner PhD
Date Submitted: 2024-04-25
Collections: Regenerative Medicine

Novel Research Tool to Study TDP-43 Dysfunction

06637

RNA biosensor CUTS-1 detects TDP-43 loss-of-function cells via cryptic exon–driven EGFP, enabling targeted therapy and tracking disease.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - RNA
Therapeutic Areas: Neuroscience
Therapeutic Indications: Alzheimer's Disease
Lead Inventor: Christopher Donnelly
Department: Med-Neurobiology
All Tech Innovators: Christopher James Donnelly
Date Submitted: 2024-02-08
Collections: Cell & Gene Therapy

Restoring Sensation: Cutting-Edge Skin Reprogramming to Combat Diabetic Nerve Damage

06619

Skin-to-Schwann-like reprogramming via TNT delivers ASK factors, restoring sensation and promoting nerve repair in diabetic neuropathy.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - DNA
Therapeutic Areas: Neuroscience
Tags: Genetics
Lead Inventor: Chandan Sen
Department: Med-Surgery
All Tech Innovators: Raghunath Reddy Raghunath Bommana
Savita Khanna
Ravichand Palakurti
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2024-01-29
Collections: Cell & Gene Therapy

Targeted HDAC 8 Inhibitors for Managing Kidney Disease

06617

Indole-based HDAC-8 inhibitors offer targeted, potentially less toxic kidney disease therapy; prototype-stage, organoid-supported efficacy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Nephrology
Therapeutic Indications: Acute Kidney Injury (AKI)
Lead Inventor: Donna Huryn
All Tech Innovators: Neil A. Hukriede
Donna Huryn
Sangeetha Subramani
Date Submitted: 2024-01-26

Novel Use of Metformin to Treat Musculoskeletal Injury

06416

Metformin advances tendon healing by reducing fibrosis and inflammation, promoting angiogenesis for safer, cost-effective tendinopathy treatment.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Neuroscience
Musculoskeletal
Lead Inventor: James Wang
Department: Med-Orthopedic Surgery
All Tech Innovators: James Huicong Wang
Jianying Zhang
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-05-23
Collections: Regenerative Medicine

Novel Glutamate Receptor Agonists

06272

Glutamate receptor agonist SYM2081 dampens dermal mast cell activation, offering potential treatments for dermatitis, rosacea, and hypersensitivity.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Dermatology
Therapeutic Indications: Dermatitis
Lead Inventor: Daniel Kaplan
Department: Med-Dermatology
All Tech Innovators: Daniel H. Kaplan
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-01-24

Novel Approach to Reverse Cerebral Cortex Decline

06081

Proteins linked to aging spine loss identified; 10 drugs may protect cognition, slowing dementia by preserving dendritic spines.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Neuroscience
Therapeutic Indications: Dementia
Alzheimer's Disease
Tags: Aging
Drug Repurposing
Lead Inventor: Robert Sweet
Department: Med-Psychiatry
All Tech Innovators: Peihao Fan
Joshua Michael Krivinko
Matthew Luke MacDonald
Date Submitted: 2022-06-30

NAMPT Inhibitors Exhibit Excellent Potency and ADME Properties

05522

Novel Nampt inhibitors deliver strong potency and favorable ADME, enabling chemotherapy and immune support benefits.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Oncology
Tags: Autoimmune
Immuno-oncology
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-10-06

Humanized Animal Models for Advanced Antibody Production

04301

Humanized mice cultivate human immune responses to produce monoclonal antibodies, enabling safer, more efficacious human antibody therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Other
Tags: Platform Technology
Lead Inventor: Moses Bility
Department: GSPH-Infectious Diseases & Microbiology
All Tech Innovators: Moses Turkle Bility
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2017-06-21

Mitoparib: A Mitochondrial PARP Inhibitor that Counteracts Metabolic Stress

03916

Mitochondria-targeted PARP inhibitor that preserves mitochondrial NAD+, preventing stress-induced necrosis without hindering nuclear DNA repair.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Hulya Bayir
Robert B. Clark
Tanja Krainz
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-04-23

Biodegradable Poly(Ester Amide) Elastomers

03590

Biodegradable poly(ester amide) elastomers: solvent-free, tunable, biocompatible scaffolds for soft tissue engineering and drug delivery.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Tags: Polymer
Platform Technology
Lead Inventor: Shilpa Sant
Department: Department of Pharmaceutical Sciences
All Tech Innovators: Shilpa Sant
Vinayak Sant
Date Submitted: 2015-04-20
Collections: Regenerative Medicine

Novel Repair and Regeneration Therapy for Glaucoma

07246

AAV-Ina overexpression promotes retinal ganglion cell survival and axon regeneration, offering neuroprotection for glaucoma with regeneration potential.

Technology Type: Therapeutic Modality
Therapeutic Areas: Neuroscience
Ophthalmology
Therapeutic Indications: Glaucoma
Tags: Drug Discovery - Target
Life Science
Lead Inventor: Kun Che Chang
Department: Med-Ophthalmology
All Tech Innovators: Kun Che Chang
Chi-Yu Chen
Date Submitted: 2025-07-11

A Novel Platform for Enhanced Inner Ear Drug Delivery and Gene Therapy

07230

Exosome-based inner ear drug delivery platform enhances RWM traversal, enabling sustained, versatile loading of drugs and gene therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Otolaryngology
Therapeutic Indications: Hearing Loss
Tags: Regenerative medicine
Platform Technology
Lead Inventor: Adele Moatti
Department: Med-Otolaryngology
All Tech Innovators: Adele Moatti
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-06-23
Collections: Regenerative Medicine

Novel Peptide Therapy to Halt the Progression of Chronic and Acute Kidney Disease

07203

HMMR-inhibiting peptides block HA signaling, halting AKI and CKD progression by reducing fibrosis, inflammation, and ERK/mTOR signaling.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Nephrology
Therapeutic Indications: Chronic Kidney Disease (CKD)
Acute Kidney Injury (AKI)
Tags: Autoimmune
Precision medicine
Critical Care
Lead Inventor: Rannar Airik
Department: Med-Pediatrics
All Tech Innovators: Rannar Airik
Merlin Airik
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2025-06-04
Collections: Cardiometabolic

Borylated Esters and Acetals as Cancer Prodrugs

06731

Boronate-protected prodrugs release cytotoxins in peroxide-rich cancer cells, enabling targeted, reduced-side-effect chemotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Lead Inventor: Paul Floreancig
Department: Chemistry
All Tech Innovators: Alexander Deiters
Paul Edward Floreancig
Paul Joseph Geaneotes
Date Submitted: 2024-04-29

Fluid Removal Algorithm for Acute Kidney Injury

05831

A standardized, data-driven fluid removal tool for ICU dialysis in AKI, aiming to reduce hypotension and complications.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Leukemia
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
John W. Mellors
Zehua Sun
Date Submitted: 2021-10-06

Novel Neutralizing Nanobodies for Coronavirus Diseases

05802

Pan-sarbecovirus nanobodies enable inhalable, stable, cost-effective COVID-19 and related coronavirus neutralization across variants.

Technology Type: Therapeutic Modality
Technology Subtype: Other Therapeutic Modality
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Other
Covid-19
Lead Inventor: Yi Shi
Department: Med-Cell Biology
All Tech Innovators: Yi Shi
Yufei Xiang
Date Submitted: 2021-09-06

Novel Treatment Approach for Antibiotic Resistance in Bacterial Pathogens Gram-Negative

05667

Cationic peptides WLBU2/PLG206 curb Gram-negative resistance by requiring multiple mutations, slowing evolution in Pseudomonas and relatives.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Infectious Disease
Lead Inventor: Vaughn Cooper
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Vaughn Scott Cooper
Alfonso Santos Lopez
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-04-13

A Novel Method to Improve Adoptive Cell Therapy

05447

Redirects T cell glucose metabolism with dichloroacetate to boost mitochondrial health, viability, and antitumor activity in adoptive cell therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Lead Inventor: Greg Delgoffe
Department: Med-Immunology
All Tech Innovators: Greg M. Delgoffe
Andrew Tyler Frisch
Date Submitted: 2020-07-16
Collections: Cell & Gene Therapy

Neuroprotective Peptide in Acute Ischemic Injury

05442

A brain-penetrant peptide (TAT-DP-2) disrupts Kv2.1 clusters to prevent delayed neuronal death after stroke.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Cardiovascular
Neuroscience
Therapeutic Indications: Stroke
Other
Lead Inventor: Elias Aizenman
Department: Med-Neurobiology
All Tech Innovators: Elias Aizenman
Jason Arnold Justice
Anthony John Schulien
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-07-09
Collections: Cardiometabolic

Insertion Unique to SARS-CoV-2 Exhibits Superantigenic Characteristics

05404

SARS-CoV-2 spike contains a unique superantigen-like site; monoclonal antibodies may block MIS-C, cytokine storms, and entry.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Covid-19
Lead Inventor: Ivet Bahar
Department: Biochemistry and Cell Biology
All Tech Innovators: Moshe Arditi MD
Ivet Bahar
Hongying Cheng
Date Submitted: 2020-06-05

Enhanced Antitumor Efficacy of Ultrasound-mediated Doxorubicin Delivery by Microbubble-liposome Complex

05168

Ultrasound-triggered microbubble-liposome delivery of doxorubicin enhances tumor kill, reduces cardiotoxicity, boosting soft-tissue sarcoma therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Lead Inventor: Flordeliza Villanueva
Department: Med-Medicine
All Tech Innovators: Xucai Chen
Mingyu He
Flordeliza S. Villanueva M.D.
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-11-14

Microsphere-Based Therapy for Reversing New-Onset Autoimmune Diabetes

01703

Innovative antisense-loaded microspheres reverses new-onset autoimmune diabetes by downregulating CD40/CD80/CD86, modulating dendritic cells.

Technology Type: Therapeutic Modality
Technology Subtype: Vaccine - subunit, recombinant, polysaccharide, or conjugate
Therapeutic Areas: Endocrinology and Metabolic Diseases
Therapeutic Indications: Diabetes
Lead Inventor: Nick Giannoukakis
Department: Med-Pathology
All Tech Innovators: Nick Giannoukakis
Massimo M. Trucco
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2008-04-17
Collections: Cardiometabolic

Novel EGFR Tumor-Associated Antigens and Enhanced Agonist Epitopes

01638

Novel EGFR tumor antigens and potent agonist epitopes enable enhanced immunotherapy and vaccines for EGFR-expressing cancers.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Oncology
Therapeutic Indications: Nasopharyngeal carcinoma (NPC)
Solid tumor
Other
Tags: Immuno-oncology
Lead Inventor: Robert Ferris
Department: Med-Otolaryngology
All Tech Innovators: Pedro Alcantara Andrade
Robert Louis Ferris
Andres Lopez Albaitero
Technology Readiness Level: 6. IND-enabling studies
Date Submitted: 2008-02-11

Targeting Cardiomyocyte Endoreplication to Prevent Hypertrophic Cardiomyopathy

07132

Inhibits PCNA-POLD1 interactions via p21 to curb cardiomyocyte endoreplication, preventing hypertrophic cardiomyopathy progression.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - RNA
Therapeutic Areas: Cardiovascular
Therapeutic Indications: Hypertrophic cardiomyopathy
Tags: Genetics
Regenerative medicine
Platform Technology
Lead Inventor: Jason Becker
Department: Med-Medicine
All Tech Innovators: Jason Robert Becker
Soumojit Pal
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-03-30
Collections: Cell & Gene Therapy
Regenerative Medicine
Cardiometabolic

HIF1 Activators as Therapeutics for Triosephosphate Isomerase Deficiency (TPI Df)

07001

HIF1-activating triazines boost TPI expression, repurposing approved PHD inhibitors (e.g., vadadustat) for TPI deficiency.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Musculoskeletal
Lead Inventor: Michael Palladino
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Michael John Palladino
Andreas Vogt
Date Submitted: 2024-12-09

Nitro-fatty Acids for Treating Aortic Aneurysm

05302

Nitro-oleic acid (nitro-fatty acid) shows promise halting abdominal aortic aneurysm progression via anti-inflammatory effects.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Therapeutic Indications: Other
Lead Inventor: Francisco Schopfer
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Yuqing Eugene Chen
Bruce A. Freeman
Francisco Jose Schopfer PhD
Date Submitted: 2020-04-13
Collections: Cardiometabolic

Use of Specific Phages for the Treatment of Non-Tuberculosis Mycobacterial Infections

05095

Phage therapy targets drug-resistant non-tuberculous Mycobacteria, enabling rapid, strain-specific treatment with minimal resistance and side effects.

Technology Type: Therapeutic Modality
Technology Subtype: Bacteriophage
Therapeutic Areas: Respiratory
Infectious Disease
Tags: Biomaterial
Lead Inventor: Graham Hatfull
Department: Distinguished Faculty-Dietrich School of Arts and Sciences
All Tech Innovators: Rebekah Marie Dedrick
Carlos Andres Guerrero
Graham F. Hatfull
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-08-20

Stimulation of Exosome Secretion

04959

A potent stimulator boosts exosome secretion up to 24-fold, enabling rapid, scalable exosome production for therapies and research.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Other
Tags: Platform Technology
Lead Inventor: Theresa Whiteside
Department: Med-Pathology
All Tech Innovators: Edwin Kerry Jackson
Nils Ludwig
Theresa L. Whiteside
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-05-19